4.51
Precedente Chiudi:
$4.84
Aprire:
$4.69
Volume 24 ore:
11,057
Relative Volume:
0.60
Capitalizzazione di mercato:
$5.94M
Reddito:
-
Utile/perdita netta:
$-38.35M
Rapporto P/E:
-3.1103
EPS:
-1.45
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
-5.67%
1M Prestazione:
-21.70%
6M Prestazione:
-69.69%
1 anno Prestazione:
-74.23%
Galecto Inc Stock (GLTO) Company Profile
Nome
Galecto Inc
Settore
Industria
Telefono
45-70-70-52-10
Indirizzo
75 STATE STREET, BOSTON
Confronta GLTO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
GLTO
Galecto Inc
|
4.51 | 5.94M | 0 | -38.35M | -36.91M | -1.45 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2020-11-23 | Iniziato | BofA Securities | Buy |
2020-11-23 | Iniziato | Credit Suisse | Outperform |
2020-11-23 | Iniziato | SVB Leerink | Outperform |
Galecto Inc Borsa (GLTO) Ultime notizie
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Galecto stock hits 52-week low at $4.39 amid market challenges - MSN
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Galecto to Participate in Upcoming Investor Conferences - The Globe and Mail
Galecto stock hits 52-week low at $4.39 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partnrs Estimates Galecto FY2024 Earnings - Defense World
Brokers Set Expectations for Galecto FY2029 Earnings - Armenian Reporter
Galecto to Participate in Upcoming Investor Conferences -February 06, 2025 at 08:01 am EST - Marketscreener.com
Biotech Spotlight: Galecto Lines Up Triple Conference Showcase for Investors - StockTitan
Where are the Opportunities in (GLTO) - Stock Traders Daily
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World
(GLTO) On The My Stocks Page - Stock Traders Daily
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Galecto CEO Hans T. Schambye sells $7,509 in shares - Investing.com
Galecto (NASDAQ:GLTO) Shares Up 22.6% – Should You Buy? - Defense World
When (GLTO) Moves Investors should Listen - Stock Traders Daily
Galecto stock plunges to 52-week low at $4.78 amid market challenges - Investing.com Australia
Galecto stock hits 52-week low at $5.26 amid market challenges - Investing.com Nigeria
Galecto stock hits 52-week low at $5.26 amid market challenges By Investing.com - Investing.com South Africa
(GLTO) Trading Signals - Stock Traders Daily
Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia
GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India
Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy
Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic
(GLTO) Investment Report - Stock Traders Daily
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
Galecto Inc Azioni (GLTO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):